Together, these considerations provide a rationale for incorporating SNHG5–GNB2 status into future biomarker-driven trials that test combinations of lncRNA-targeted therapeutics, pathway inhibitors and immunotherapy in metastatic CRC. This evidence concerns the gene SNHG5 and colorectal carcinoma.